Abstract
Denosumab is a novel antiresorptive drug that has been approved for use as a first-line drug for primary and secondary prevention of osteoporotic fractures. The authors discuss the mechanism of action of denosumab, review the evidence for its efficacy and safety in patients with osteoporosis, and offer recommendations for its use in clinical practice.
| Original language | English |
|---|---|
| Journal | Cleveland Clinic Journal of Medicine |
| Volume | 82 |
| Issue number | 2 |
| Pages (from-to) | 105-14 |
| Number of pages | 10 |
| ISSN | 0891-1150 |
| DOIs | |
| Publication status | Published - Feb 2015 |
Keywords
- Absorptiometry, Photon
- Aged
- Antibodies, Monoclonal, Humanized
- Bone Density
- Bone Density Conservation Agents
- Denosumab
- Female
- Humans
- Lumbar Vertebrae
- Osteoporosis
- Osteoporotic Fractures
- RANK Ligand
- Spinal Fractures
- Thoracic Vertebrae